Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

被引:84
作者
Giles, F [1 ]
Estey, E [1 ]
O'Brien, S [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
D O I
10.1002/cncr.11791
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) linked to N-acetvl-y calicheamicin 1,2-dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AMI,) in a Subset of older patients. Data oil studies in AML with GO-based regimens have been reported rapidly in addition to new observations on the target antigen, CD33. These data indicate promising new areas of investigation with GO, including its application as maintenance therapy in patients with AML and as an induction and/or maintenance agent in patients with acute promyelocytic leukemia;, and they also have highlighted challenges in the development of GO, particularly its association with hepatic venoocclusive disease. In vitro data oil the mechanism of action of GO may be particularly helpful in the design of future clinical studies. Cancer 2003;98: 2095-104. (C) 2003 American Cancer Society.
引用
收藏
页码:2095 / 2104
页数:10
相关论文
共 66 条
[1]   Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia [J].
Alvarado, Y ;
Tsimberidou, A ;
Kantarjian, H ;
Cortes, J ;
Garcia-Manero, G ;
Faderl, S ;
Thomas, D ;
Estey, E ;
Giles, FJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (01) :87-90
[2]  
Amadori S, 2001, BLOOD, V98, p587A
[3]  
AMICO D, 2003, BLOOD, V6, P6
[4]   Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia [J].
Apostolidou, E ;
Cortes, J ;
Tsimberidou, A ;
Estey, E ;
Kantarjian, H ;
Giles, FJ .
LEUKEMIA RESEARCH, 2003, 27 (10) :887-891
[5]   Veno-occlusive disease of the liver [J].
Bearman, SI .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (02) :103-109
[6]   Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate [J].
Bernstein, ID .
LEUKEMIA, 2000, 14 (03) :474-475
[7]   CD33 as a target for selective ablation of acute myeloid leukemia [J].
Bernstein, ID .
CLINICAL LYMPHOMA, 2002, 2 :S9-S11
[8]  
Bross PF, 2001, CLIN CANCER RES, V7, P1490
[9]   Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study [J].
Chopra, R ;
Eaton, JD ;
Grassi, A ;
Potter, M ;
Shaw, B ;
Salat, C ;
Neumeister, P ;
Finazzi, G ;
Iacobelli, M ;
Bowyer, K ;
Prentice, HG ;
Barbui, T .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (04) :1122-1129
[10]   Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease [J].
Cohen, AD ;
Luger, SM ;
Sickles, C ;
Mangan, PA ;
Porter, DL ;
Schuster, SJ ;
Tsai, DE ;
Nasta, S ;
Gewirtz, AM ;
Stadtmauer, EA .
BONE MARROW TRANSPLANTATION, 2002, 30 (01) :23-28